echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation

    Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 22, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Luoxin Pharmaceutical Group Co.


    Omeprazole is the world's first proton pump inhibitor.


    Omeprazole sodium was first marketed in Luxembourg in 1987 and in the United States in 1989.


    According to IQVIA data, the global sales of omeprazole sodium for injection in 2019 were US$590 million (calculated at the ex-factory price), and the sales amount in my country was RMB 4.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.